Aptevo Therapeutics Inc - APVO STOCK NEWS

Aptevo Therapeutics Inc. (NASDAQ:APVO) announced that its research on APVO436, a bispecific antibody for acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), has been published in Cancers. The study indicated that only 21.7% of 46 patients treated with APVO436 developed cytokine release syndrome (CRS), a common side effect of such therapies. The severe CRS cases were low at 8.7%. This promising data highlights APVO436 as a potential new treatment option for patients with these challenging blood cancers.

Aptevo Therapeutics announced that its lead candidate, APVO436, showed clinical activity and an acceptable safety profile for treating adults with myelodysplastic syndrome (MDS). The article published in Frontiers in Aging discusses the potential of bispecific antibodies to target both MDS clones and immunosuppressive cells, crucial for high-risk MDS patients. In a study, APVO436 induced complete remissions in 3 out of 6 evaluable high-risk MDS patients, suggesting its promise as a new anti-MDS drug candidate.

Aptevo Therapeutics announced promising results from a Phase 1 clinical study of its lead drug candidate, APVO436, for patients with relapsed acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). The study involved 46 adult patients, with 27.5% achieving favorable responses, including complete remissions. APVO436 demonstrated a favorable safety profile, with manageable adverse events primarily involving infusion reactions. The median survival for responding patients exceeded 300 days, compared to 100 days for others. These findings support further clinical development of APVO436 as a potential new treatment option.

Aptevo Therapeutics (APVO) reported financial results for Q2 2021, highlighting a net loss of $7.9 million or $1.75 per share, compared to a loss of $6.8 million or $2.10 per share in Q2 2020. Cash and cash equivalents totaled $61.7 million, with a runway through Q3 2022. The company advanced its Phase 1 trial for APVO436 in treating acute myeloid leukemia, showing promising safety and preliminary efficacy. Aptevo was also added to the Russell Microcap Index, reflecting growth and increased visibility in the market.

Aptevo Therapeutics (NASDAQ:APVO), a clinical-stage biotechnology company, announced that Dr. Jane Gross will speak at the Cambridge Health Institute PEGS Virtual Conference from July 19-22, 2021. Her presentation, titled Generating Immuno-Modulatory Bispecific Therapeutic Candidates for the Treatment of Hematologic and Solid Tumors, is scheduled for July 19 at 11:25 AM ET. Dr. Gross will also participate in a panel discussion on bispecific antibodies versus CAR T therapies at noon on the same day. Aptevo aims to leverage its ADAPTIR technologies for novel cancer treatments.

Aptevo Therapeutics (NASDAQ:APVO) has been added to the Russell Microcap Index, effective June 28, 2021. This membership, determined by market capitalization, enhances share valuation and presents opportunities for potential investors. The company recently completed a phase 1b clinical trial of its lead drug candidate, APVO436, for acute myeloid leukemia, achieving the primary endpoint of identifying a recommended phase 2 dose. Aptevo's proprietary ADAPTIR platforms enable the development of advanced immunotherapies targeting challenging cancers.

Aptevo Therapeutics has initiated the expansion phase of its clinical trial for APVO436, aimed at treating adult patients with acute myeloid leukemia (AML). Following a successful dose escalation phase, the new multi-center trial will enroll 90 patients across five cohorts, evaluating the drug's safety and efficacy when combined with standard treatments. Positive results from the initial phase highlighted a manageable side effect profile and no severe neutropenia, promising potential for APVO436's integration into standard AML treatments.

Aptevo Therapeutics (NASDAQ:APVO) announced results from a Phase 1 dose escalation trial of APVO436, its lead candidate for acute myeloid leukemia (AML) and myelodysplastic syndromes. The study enrolled 46 patients, demonstrating a favorable safety profile with no severe neutropenia, a common issue with CD123-targeting therapies. The trial identified an active dose for advanced studies and reported encouraging signs of clinical activity, including stabilization and complete remissions in several patients. Aptevo plans to submit the data for publication later this year.

Aptevo Therapeutics reported Q1 2021 financial results, highlighting ongoing progress in the Phase 1 trial of APVO436 for Acute Myeloid Leukemia and High-Grade Myelodysplastic Syndrome. As of March 31, 2021, the company had cash and cash equivalents of $58.8 million. They received $35 million from a royalty purchase agreement with HCR and recorded $2.4 million in royalty revenue from Pfizer's RUXIENCE. However, Aptevo reported a net loss of $7.3 million, or $1.64 per share, compared to a net income of $2.9 million in Q1 2020.